Titre : Torémifène

Torémifène : Questions médicales fréquentes

Termes MeSH sélectionnés :

Transcriptome
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Torémifène : Questions médicales les plus fréquentes", "headline": "Torémifène : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Torémifène : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-22", "dateModified": "2025-03-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Torémifène" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tamoxifène", "url": "https://questionsmedicales.fr/mesh/D013629", "about": { "@type": "MedicalCondition", "name": "Tamoxifène", "code": { "@type": "MedicalCode", "code": "D013629", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.455.426.559.389.150.700.900" } } }, "about": { "@type": "MedicalCondition", "name": "Torémifène", "alternateName": "Toremifene", "code": { "@type": "MedicalCode", "code": "D017312", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Alexander N Stukov", "url": "https://questionsmedicales.fr/author/Alexander%20N%20Stukov", "affiliation": { "@type": "Organization", "name": "Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N. N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia." } }, { "@type": "Person", "name": "Mikhail A Osipov", "url": "https://questionsmedicales.fr/author/Mikhail%20A%20Osipov", "affiliation": { "@type": "Organization", "name": "Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N. N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia." } }, { "@type": "Person", "name": "Tatjana Y Semiglazova", "url": "https://questionsmedicales.fr/author/Tatjana%20Y%20Semiglazova", "affiliation": { "@type": "Organization", "name": "Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N. N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia." } }, { "@type": "Person", "name": "Larisa V Filatova", "url": "https://questionsmedicales.fr/author/Larisa%20V%20Filatova", "affiliation": { "@type": "Organization", "name": "Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N. N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia." } }, { "@type": "Person", "name": "Valerij A Alexandrov", "url": "https://questionsmedicales.fr/author/Valerij%20A%20Alexandrov", "affiliation": { "@type": "Organization", "name": "Laboratory of Cancer Chemoprevention and Oncopharmacology, N. N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Single-nucleus transcriptomic profiling of human orbitofrontal cortex reveals convergent effects of aging and psychiatric disease.", "datePublished": "2024-09-03", "url": "https://questionsmedicales.fr/article/39227716", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41593-024-01742-z" } }, { "@type": "ScholarlyArticle", "name": "Integration of Gut Microbiota with Transcriptomic and Metabolomic Profiling Reveals Growth Differences in Male Giant River Prawns (", "datePublished": "2024-08-31", "url": "https://questionsmedicales.fr/article/39272324", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ani14172539" } }, { "@type": "ScholarlyArticle", "name": "Transcriptome-based identification of key actin-binding proteins associated with high metastatic potential in breast cancer.", "datePublished": "2024-08-30", "url": "https://questionsmedicales.fr/article/39281318", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fmolb.2024.1440276" } }, { "@type": "ScholarlyArticle", "name": "Single-cell transcriptomics reveals tumor microenvironment remodeling in hepatocellular carcinoma with varying tumor subclonal complexity.", "datePublished": "2024-08-29", "url": "https://questionsmedicales.fr/article/39268081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fgene.2024.1467682" } }, { "@type": "ScholarlyArticle", "name": "Transcriptomic and Metabolomic Analysis Reveals the Potential Roles of Polyphenols and Flavonoids in Response to Sunburn Stress in Chinese Olive (", "datePublished": "2024-08-25", "url": "https://questionsmedicales.fr/article/39273853", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/plants13172369" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés chimiques organiques", "item": "https://questionsmedicales.fr/mesh/D009930" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures", "item": "https://questionsmedicales.fr/mesh/D006838" }, { "@type": "ListItem", "position": 4, "name": "Hydrocarbures cycliques", "item": "https://questionsmedicales.fr/mesh/D006844" }, { "@type": "ListItem", "position": 5, "name": "Hydrocarbures aromatiques", "item": "https://questionsmedicales.fr/mesh/D006841" }, { "@type": "ListItem", "position": 6, "name": "Dérivés du benzène", "item": "https://questionsmedicales.fr/mesh/D001555" }, { "@type": "ListItem", "position": 7, "name": "Composés benzylidéniques", "item": "https://questionsmedicales.fr/mesh/D001597" }, { "@type": "ListItem", "position": 8, "name": "Stilbènes", "item": "https://questionsmedicales.fr/mesh/D013267" }, { "@type": "ListItem", "position": 9, "name": "Tamoxifène", "item": "https://questionsmedicales.fr/mesh/D013629" }, { "@type": "ListItem", "position": 10, "name": "Torémifène", "item": "https://questionsmedicales.fr/mesh/D017312" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Torémifène - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Torémifène", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Torémifène", "description": "Comment le torémifène est-il prescrit ?\nQuels tests précèdent la prescription de torémifène ?\nLe torémifène est-il utilisé pour d'autres cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nLe torémifène nécessite-t-il un suivi régulier ?", "url": "https://questionsmedicales.fr/mesh/D017312?mesh_terms=Transcriptome&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Torémifène", "description": "Quels sont les effets secondaires courants du torémifène ?\nLe torémifène cause-t-il des douleurs articulaires ?\nY a-t-il des symptômes d'allergie au torémifène ?\nLe torémifène affecte-t-il l'humeur ?\nQuels symptômes nécessitent une consultation immédiate ?", "url": "https://questionsmedicales.fr/mesh/D017312?mesh_terms=Transcriptome&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Torémifène", "description": "Le torémifène est-il utilisé en prévention du cancer ?\nQuelles sont les recommandations préventives ?\nLe mode de vie influence-t-il l'efficacité du torémifène ?\nY a-t-il des alternatives au torémifène pour la prévention ?\nLe torémifène est-il efficace chez les femmes jeunes ?", "url": "https://questionsmedicales.fr/mesh/D017312?mesh_terms=Transcriptome&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Torémifène", "description": "Comment le torémifène est-il administré ?\nQuelle est la posologie standard du torémifène ?\nLe torémifène peut-il être combiné avec d'autres traitements ?\nCombien de temps dure un traitement au torémifène ?\nLe torémifène nécessite-t-il des ajustements de dose ?", "url": "https://questionsmedicales.fr/mesh/D017312?mesh_terms=Transcriptome&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Torémifène", "description": "Quelles complications peuvent survenir avec le torémifène ?\nLe torémifène augmente-t-il le risque de cancer de l'utérus ?\nComment gérer les complications du torémifène ?\nLe torémifène peut-il causer des problèmes cardiaques ?\nQuels signes indiquent une complication grave ?", "url": "https://questionsmedicales.fr/mesh/D017312?mesh_terms=Transcriptome&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Torémifène", "description": "Quels sont les facteurs de risque pour le cancer du sein ?\nLe surpoids est-il un facteur de risque ?\nLes antécédents familiaux influencent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?\nL'âge de la première menstruation influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D017312?mesh_terms=Transcriptome&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le torémifène est-il prescrit ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il est prescrit pour traiter le cancer du sein hormono-dépendant chez les femmes." } }, { "@type": "Question", "name": "Quels tests précèdent la prescription de torémifène ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests hormonaux et des biopsies peuvent être effectués pour évaluer le cancer." } }, { "@type": "Question", "name": "Le torémifène est-il utilisé pour d'autres cancers ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il est principalement utilisé pour le cancer du sein, mais des études explorent d'autres indications." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont surveillés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux d'œstrogènes et de récepteurs hormonaux sont souvent surveillés." } }, { "@type": "Question", "name": "Le torémifène nécessite-t-il un suivi régulier ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour évaluer l'efficacité et les effets secondaires." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants du torémifène ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent bouffées de chaleur, nausées et fatigue." } }, { "@type": "Question", "name": "Le torémifène cause-t-il des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines patientes rapportent des douleurs articulaires comme effet secondaire." } }, { "@type": "Question", "name": "Y a-t-il des symptômes d'allergie au torémifène ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des réactions allergiques peuvent survenir, comme éruptions cutanées ou démangeaisons." } }, { "@type": "Question", "name": "Le torémifène affecte-t-il l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certaines patientes peuvent éprouver des changements d'humeur ou de l'anxiété." } }, { "@type": "Question", "name": "Quels symptômes nécessitent une consultation immédiate ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs thoraciques, des saignements inhabituels ou des symptômes allergiques graves." } }, { "@type": "Question", "name": "Le torémifène est-il utilisé en prévention du cancer ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il est parfois utilisé pour réduire le risque de cancer du sein chez les femmes à risque élevé." } }, { "@type": "Question", "name": "Quelles sont les recommandations préventives ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les femmes à risque élevé devraient discuter des options de prévention avec leur médecin." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il l'efficacité du torémifène ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut améliorer l'efficacité du traitement et réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des alternatives au torémifène pour la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "D'autres options incluent les inhibiteurs de l'aromatase et les interventions chirurgicales." } }, { "@type": "Question", "name": "Le torémifène est-il efficace chez les femmes jeunes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être efficace, mais les décisions doivent être basées sur des évaluations individuelles." } }, { "@type": "Question", "name": "Comment le torémifène est-il administré ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement administré par voie orale sous forme de comprimés." } }, { "@type": "Question", "name": "Quelle est la posologie standard du torémifène ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie standard est souvent de 60 mg par jour, mais peut varier selon le cas." } }, { "@type": "Question", "name": "Le torémifène peut-il être combiné avec d'autres traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être utilisé en association avec d'autres thérapies comme la chimiothérapie." } }, { "@type": "Question", "name": "Combien de temps dure un traitement au torémifène ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement peut varier, souvent plusieurs mois à plusieurs années." } }, { "@type": "Question", "name": "Le torémifène nécessite-t-il des ajustements de dose ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des ajustements peuvent être nécessaires en fonction des effets secondaires et de la réponse." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le torémifène ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des thromboses veineuses profondes peuvent survenir." } }, { "@type": "Question", "name": "Le torémifène augmente-t-il le risque de cancer de l'utérus ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut augmenter le risque de cancer de l'utérus chez certaines patientes." } }, { "@type": "Question", "name": "Comment gérer les complications du torémifène ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi régulier et des ajustements de traitement si nécessaire." } }, { "@type": "Question", "name": "Le torémifène peut-il causer des problèmes cardiaques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes cardiaques sont rares mais peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs thoraciques, des saignements vaginaux ou des symptômes neurologiques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour le cancer du sein ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les antécédents familiaux et l'exposition aux œstrogènes." } }, { "@type": "Question", "name": "Le surpoids est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le surpoids et l'obésité augmentent le risque de cancer du sein et d'autres cancers." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer du sein augmentent le risque individuel." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme est associé à divers cancers, y compris le cancer du sein." } }, { "@type": "Question", "name": "L'âge de la première menstruation influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une menstruation précoce peut augmenter le risque de cancer du sein plus tard." } } ] } ] }

Sources (10000 au total)

Transcriptome-based identification of key actin-binding proteins associated with high metastatic potential in breast cancer.

Actin-binding proteins (ABPs) are essential for the regulation of morphological plasticity required for tumor cells to metastasize. The aim of this study was to perform an unbiased bioinformatic appro... Microarray data from 181 primary breast cancer samples from our hospital were used, and all genes belonging to the Gene Ontology term actin cytoskeleton organization were obtained from QuickGO. Associ...

Single-cell transcriptomics reveals tumor microenvironment remodeling in hepatocellular carcinoma with varying tumor subclonal complexity.

The complexity of tumor cell subclonal structure has been extensively investigated in hepatocellular carcinoma. However, the role of subclonal complexity in reshaping the tumor microenvironment (TME) ... We integrated single-cell transcriptome sequencing data from four independent HCC cohorts, involving 30 samples, to decode the associations between tumor subclonal complexity and the TME. We proposed ... We found that tumor cells in the high-complexity group originated from the cell lineage with FGB overexpression and exhibited high levels of transcription factors associated with poor survival. In con... Our study sheds light on the intricate relationship between the complexity of subclonal structure and the TME, offering novel insights into potential therapeutic targets for HCC....

Diagnostic value of the Sirtuins family in acute rejection of kidney transplantation assessed on the basis of transcriptomics and animal experiments.

The Sirtuins (SIRT) family plays a key role in the diagnosis and treatment of many renal diseases, but no studies have been reported in acute rejection of kidney transplantation. The aim of this study... We first explored the SIRT family expression profile in renal tissues using the HPA database; subsequently, we explored the potential biological functions and mechanistic changes during acute rejectio... We found that all seven SIRT family members were located and expressed in renal tissues. The results of enrichment analysis revealed that a large number of immune-related biological functions and path... The SIRT family has significant changes during acute rejection in kidney transplantation, and the SIRT family may be able to serve as a potential therapeutic target for alleviating acute rejection in ...

Integrated metabolomic and transcriptomic analysis reveals the effects and mechanisms of Jinqi Jiangtang tablets on type 2 diabetes.

Type 2 diabetes (T2DM) is one of the major metabolic diseases and poses a serious challenge to human life and global economic development. Jinqi Jiangtang Tablets (JQJT) is effective in ameliorating t... This study integrated metabolomics and transcriptomics to reveal the mechanism by which JQJT improves T2DM.... The T2DM mouse model was established, and the effects of JQJT on improving T2DM were evaluated by determining the levels of blood lipids, fasting blood glucose (FBG), insulin metabolism and hepatic li... JQJT reduced FBG and lipid levels, improved insulin resistance (IR) and hepatic lipoatrophy in mice. A total of 35 differentially abundant metabolites were identified by metabolomics, and 328 differen... JQJT improved IR in T2DM mice by regulating the insulin signaling pathway, improving glycogen synthesis and glycolysis, and increasing hepatic triglyceride and fatty acid metabolism....